Company
Stereotaxis
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
9
510(k), De Novo and PMA
Device trials
9
As lead sponsor, any status
Adverse event reports
1
Received Nov 1, 2025 to Nov 20, 2026
Recall records
7
One per recalled product
Stereotaxis is on our public-company list (ticker STXS). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
STXS
NYSE · Stereotaxis, Inc.
Public float
$150M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$32.4M
Fiscal year ending Dec 31, 2025
Net income
-$21.6M
Fiscal year ending Dec 31, 2025
R&D spending
$9.4M
Fiscal year ending Dec 31, 2025
Cash
$4.0M
As of Sep 30, 2026
Long-term debt
$2.5M
As of Sep 30, 2026
Shares outstanding
100.9M
As of Oct 31, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | $15.7M | – | – |
| 2024 | – | $297K | – | – |
| 2023 | – | $81K | – | – |
| 2022 | – | $220K | – | – |
| 2021 | – | $547K | – | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2024 | Equity Issued in a merger or acquisition; not counted as money raised | $3.0M | Open-ended | 1 | Rule 506(b) | Form D ↗Aug 15, 2024 |
| Aug 7, 2019 | Equity | $25.0M | $25.0M | 6 | Rule 506(b)Agent: Cowen and Company LLC | Form D ↗Aug 21, 2019 |
| Sep 29, 2016 | Equity | $24.0M | $24.0M | 12 | Rule 506(b) | Form D ↗Oct 5, 2016 |
2 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- Stereotaxis, Inc.
- Headquarters
- St.Louis, Missouri
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Technology
- SEC filer
- CIK 1289340 ↗
Executives, directors and promoters
As listed on the latest Form D.
8 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 9 since 2015.
- GenesisX RMN510(k)
K262744 · Decided Aug 27, 2026 · 24 days after receipt
Device type: System, Catheter Control, Steerable (DXX) · Cardiology
- Synchrony510(k)
K253473 · Decided Apr 1, 2026 · 173 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
P240014 · Decided Jan 5, 2026 · 633 days after receipt
Device type: Cardiac ablation percutaneous catheter (LPB) · Cardiology
6 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT06019845 · 150 participants (planned) · Start Jan 2, 2024 · Primary completion Dec 31, 2027
Device: MAGiC™ · For: Arrhythmias, Cardiac
Sites: Copenhagen, Denmark; Vilnius, Lithuania; Rotterdam, Netherlands · 4 sites in all
- MAGiC - Congenital Heart DIseaseNot yet recruiting
NCT07812818 · 40 participants (planned) · Start Oct 31, 2026 · Primary completion Jan 31, 2029
Device: Cardiac ablation using the MAGiC Ablation Catheter · For: Supraventricular Tachycardia (SVT); Congenital Heart Disease (CHD)
NCT04171479 · 40 participants · Start Oct 2, 2020 · Primary completion Mar 30, 2023
Device: Epicardial mapping and/or ablation · For: Ventricular Tachycardia; Premature Ventricular Contraction
Sites: Prague, Czechia; Amsterdam, Netherlands; Rotterdam, Netherlands
6 more trials with a free account
Reports received
1
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
1
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 1 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 1 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0430-2021 · Started Sep 21, 2020
Reason given: There is a potential for fire in the inside computer cabinet.
Cause as FDA categorized it: Device Design · Device type: Catheter Remote Control System (PJB)
Z-0590-04 · Started Jan 27, 2004 · Posted by FDA Jul 20, 2004
Reason given: The magnet at the end of the guidewire could break off.
Cause as FDA categorized it: Other · Device type: Product code (NFN)
Z-0591-04 · Started Jan 27, 2004 · Posted by FDA Jul 20, 2004
Reason given: The magnet at the end of the guidewire could break off.
Cause as FDA categorized it: Other · Device type: Product code (NFN)
4 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.